格隆汇1月26日丨福安药业(300194.SZ)公布，全资子公司福安药业集团宁波天衡制药有限公司（简 称"天衡制药"）于近日收到国家药品监督管理局签发的药品注册证书，药品名称：盐酸尼卡地平注射 液。盐酸尼卡地平注射液适用于手术时异常高血压的紧急处理、高血压急症。 ...

Core Insights - A new potassium hydrogen phosphate injection (Shanweixi) has been approved for market release by the National Medical Products Administration, entering a growing market with annual sales exceeding 400 million yuan and a year-on-year growth of 27.3% [1][4]. Market Overview - The compound potassium hydrogen phosphate injection is crucial for correcting hypophosphatemia in adults and children, especially when oral supplementation is not feasible, serving as a vital intravenous electrolyte replenishment solution [4]. - The product has been included in the National Medical Insurance Category B for several years, indicating a mature clinical understanding and usage [4]. - Market data from the MoSheng Pharmaceutical Database shows stable growth over the past three years, with sales expected to exceed 400 million yuan in 2024, reflecting a 27.3% increase [4]. Competitive Landscape - Prior to this approval, 24 pharmaceutical companies already held production licenses for this product, with 19 having passed consistency evaluations, indicating a stable competitive landscape [6]. - Despite the existing competition, there remains strong interest, with 15 additional companies currently in the process of applying for generic drug approvals, highlighting ongoing optimism regarding the market value of this product [6][9]. Future Outlook - For new entrants in the pharmaceutical sector, despite facing significant competition, the continuous growth of the market size and clear clinical positioning still provide opportunities for market entry [9]. - As more companies join the market, competition is expected to intensify, which may enhance product accessibility and optimize clinical medication costs [12].

Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its "Nicardipine Hydrochloride Injection," which is intended for emergency treatment of abnormal hypertension during surgery and hypertensive emergencies [1][2] Group 1: Product Approval and Market Potential - The approval of Nicardipine Hydrochloride Injection is significant as it is recommended in various hypertension management guidelines, including the 2020 International Society of Hypertension's Global Hypertension Practice Guidelines and the Chinese Hypertension Emergency Diagnosis and Treatment Guidelines [1][2] - The sales scale of Nicardipine Hydrochloride Injection in Chinese public medical institutions is projected to exceed 600 million RMB in 2024, with a double-digit growth rate from 2022 to 2024, showing year-on-year increases of 35.71%, 16.09%, and 14.14% respectively [1] Group 2: Product Advantages and Market Position - Nicardipine Hydrochloride Injection is characterized by rapid onset, stable blood pressure reduction, and comprehensive organ protection, with non-toxic metabolites and enhanced vascular selectivity, making it safer for patients [2] - Fosen Pharmaceutical offers a complete range of specifications for Nicardipine Hydrochloride Injection, including 5ml:5mg, 2ml:2mg, and 10ml:10mg, catering to diverse patient treatment needs and achieving high market recognition [2] - The quality and efficacy of Fosen Pharmaceutical's Nicardipine Hydrochloride Injection are consistent with reference formulations, allowing it to serve as a substitute for the original drug in clinical settings [2]

Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its product, Nicardipine Hydrochloride Injection, which is intended for the emergency management of abnormal hypertension during surgery and hypertensive emergencies [1][2] Group 1: Product Approval and Market Potential - The consistency evaluation application for Nicardipine Hydrochloride Injection has been approved, indicating its readiness for clinical use [1] - The sales scale of Nicardipine Hydrochloride Injection in Chinese public medical institutions is projected to exceed 600 million RMB in 2024, with a double-digit growth rate expected from 2022 to 2024, showing year-on-year increases of 35.71%, 16.09%, and 14.14% respectively [1] - The product is recognized as a first-line treatment in various hypertension management guidelines, including the 2020 International Society of Hypertension's Global Hypertension Practice Guidelines and the Chinese Hypertension Emergency Diagnosis and Treatment Guidelines [1] Group 2: Product Advantages and Specifications - Nicardipine Hydrochloride Injection is noted for its rapid onset, stable blood pressure reduction, and comprehensive organ protection, with a non-toxic metabolic profile and enhanced vascular selectivity [2] - The company has been selling the 5ml:5mg specification in the domestic market for several years, achieving high market recognition, and has also received approval for additional specifications of 2ml:2mg and 10ml:10mg [2] - Fosen Pharmaceutical is one of the few companies in China to offer a complete range of specifications for Nicardipine Hydrochloride Injection, catering to diverse patient treatment needs [2]

Core Viewpoint - Fosen Pharmaceutical has received approval from the National Medical Products Administration of China for its "Nicardipine Hydrochloride Injection," which is intended for the emergency management of abnormal hypertension during surgery and hypertensive emergencies [1][2] Group 1: Product Approval and Market Potential - The consistency evaluation application for Nicardipine Hydrochloride Injection has been approved, indicating its readiness for clinical use in critical situations [1] - The sales scale of Nicardipine Hydrochloride Injection in Chinese public medical institutions is expected to exceed 600 million RMB in 2024, with a double-digit growth rate projected from 2022 to 2024, showing year-on-year increases of 35.71%, 16.09%, and 14.14% respectively [1] - The product is recognized as a first-line treatment in various hypertension management guidelines, including the 2020 International Society of Hypertension's Global Hypertension Practice Guidelines and the Chinese Hypertension Emergency Diagnosis and Treatment Guidelines [1] Group 2: Product Features and Competitive Advantage - Nicardipine Hydrochloride Injection is characterized by rapid onset, stable blood pressure reduction, and comprehensive organ protection, with non-toxic metabolites and enhanced safety [2] - The company offers a complete range of specifications for Nicardipine Hydrochloride Injection, including 5ml:5mg, 2ml:2mg, and 10ml:10mg, catering to diverse patient needs [2] - The quality and efficacy of Fosen Pharmaceutical's Nicardipine Hydrochloride Injection are consistent with reference formulations, allowing it to serve as a substitute for the original drug in clinical settings [2]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

Core Viewpoint - The company Huayu Pharmaceutical (688553.SH) has received approval from the National Medical Products Administration for its product, Nicardipine Hydrochloride Injection, which is used for the emergency treatment of abnormal high blood pressure during surgery [1] Group 1: Product Details - Nicardipine Hydrochloride acts as a calcium channel blocker, inhibiting the influx of calcium ions into vascular smooth muscle cells, leading to vasodilation [1] - The calcium antagonistic effect of Nicardipine on vascular smooth muscle is 30,000 times stronger than its effect on myocardial tissue, indicating a high selectivity for blood vessels compared to other calcium channel blockers such as Nifedipine, Verapamil, and Diltiazem [1] Group 2: Clinical Application - The injection is clinically indicated for the emergency management of hypertensive crises and abnormal high blood pressure during surgical procedures [1]

Core Viewpoint - The company Huiyu Pharmaceutical has received approval from the National Medical Products Administration for its product, Nicardipine Hydrochloride Injection, which is classified as a Class 4 chemical drug and is considered to have passed the consistency evaluation of generic drug quality and efficacy [2] Group 1: Product Approval - The product Nicardipine Hydrochloride Injection is intended for the emergency treatment of abnormal hypertension during surgery and hypertensive emergencies [2] - The approval of the drug registration certificate is a significant milestone for the company, although it is noted that the impact on the company's operating performance in the short term is not substantial [2] Group 2: Market Potential - According to data from Minet, the sales revenue of Nicardipine Hydrochloride Injection in urban public hospitals in China is projected to be approximately 306 million yuan in the first half of 2025 [2] - The company has initiated preparatory work for the product's market launch, but there is considerable uncertainty regarding its potential to generate significant revenue in the future [2]

Core Viewpoint - The company Huayu Pharmaceutical (688553) has received approval from the National Medical Products Administration for its product, Nicardipine Hydrochloride Injection, which is used for the emergency treatment of abnormal hypertension during surgery and hypertensive emergencies [1] Group 1 - The product Nicardipine Hydrochloride Injection has been granted a drug registration certificate [1] - The clinical application of the product focuses on managing high blood pressure in urgent medical situations [1]

Group 1 - Silver prices have surged to a historic high of $60, significantly outperforming gold, with the gold-silver ratio dropping to 69, the lowest since July 2021 [2][41] - Standard Chartered's Suki Cooper noted that while silver's price momentum is supported by strong fundamentals, normalization of market dynamics may lead to short-term volatility [2][41] - The recent increase in silver prices is expected to face a correction before reaching new highs, influenced by reduced demand in India and replenished London inventories [2][41] Group 2 - The major asset restructuring between Haiguang Information and Zhongke Shuguang has been terminated due to unfavorable market conditions and the complexity of the transaction [3][42] - Both companies stated that the termination of the transaction will not adversely affect their production, operations, or financial status [3][42] Group 3 - The AI sector is experiencing a global investment shift, with international funds increasingly targeting China's technology sector due to its valuation advantages and complete industrial ecosystem [5][44] - Despite concerns over potential AI bubbles, major asset management firms continue to view artificial intelligence as a core investment theme for 2026 [5][44] - The Chinese technology sector is becoming a new battleground for global capital, driven by its manufacturing capabilities and market potential [5][44] Group 4 - The wholesale price of Feitian Moutai has dropped to 1,520 yuan per bottle, a 43% decrease over two years, nearing the official price of 1,499 yuan [6][45] - There are speculations regarding whether the manufacturer has stopped supplying distributors to control prices amid this decline [6][45] Group 5 - A new platform for the consolidation of polysilicon production capacity has been established, named Beijing Guanghe Qiancheng Technology Co., Ltd., with a registered capital of 3 billion yuan [7][46] - This platform aims to explore strategic cooperation opportunities within the industry, including technology upgrades and market expansion [7][46] Group 6 - The second-hand housing market in four first-tier cities has seen a significant recovery, with cumulative transactions reaching 519,000 units by November, surpassing the previous year's figures [8][47] - Analysts predict that this trend may continue into 2026, supported by expected monetary policy easing [8][47]